- Home
- RPTX vs ACET Comparison
RPTX vs ACET Comparison
Compare RPTX & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- ACET
- Stock Information
- Founded
- RPTX 2016
- ACET 1947
- Country
- RPTX Canada
- ACET United States
- Employees
- RPTX N/A
- ACET N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- RPTX Health Care
- ACET Health Care
- Exchange
- RPTX Nasdaq
- ACET Nasdaq
- Market Cap
- RPTX 53.2M
- ACET 44.4M
- IPO Year
- RPTX 2020
- ACET N/A
- Fundamental
- Price
- RPTX $0.93
- ACET $0.57
- Analyst Decision
- RPTX Strong Buy
- ACET Buy
- Analyst Count
- RPTX 3
- ACET 6
- Target Price
- RPTX $4.50
- ACET $6.00
- AVG Volume (30 Days)
- RPTX 266.1K
- ACET 569.4K
- Earning Date
- RPTX 05-06-2025
- ACET 05-13-2025
- Dividend Yield
- RPTX N/A
- ACET N/A
- EPS Growth
- RPTX N/A
- ACET N/A
- EPS
- RPTX N/A
- ACET N/A
- Revenue
- RPTX $53,477,000.00
- ACET N/A
- Revenue This Year
- RPTX N/A
- ACET N/A
- Revenue Next Year
- RPTX $2.61
- ACET N/A
- P/E Ratio
- RPTX N/A
- ACET N/A
- Revenue Growth
- RPTX 4.58
- ACET N/A
- 52 Week Low
- RPTX $0.89
- ACET $0.45
- 52 Week High
- RPTX $4.29
- ACET $2.35
- Technical
- Relative Strength Index (RSI)
- RPTX 34.51
- ACET 36.10
- Support Level
- RPTX $0.89
- ACET $0.45
- Resistance Level
- RPTX $1.02
- ACET $0.67
- Average True Range (ATR)
- RPTX 0.07
- ACET 0.07
- MACD
- RPTX -0.01
- ACET -0.02
- Stochastic Oscillator
- RPTX 19.10
- ACET 25.48
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.